Bristol Myers Pledges To Offload Acceleron Shares: Bloomberg

  • Bristol-Myers Squibb Co BMY is planning to tender its shares in Acceleron Pharma Inc XLRN after Merck & Co Inc MRK agreed to buy the biotechnology company for $11.5 billion, Bloomberg reported citing people with knowledge of the matter.
  • Bristol-Myers holds an 11.5% stake in Acceleron. Selling the stake will bring the Merck deal closer to completion.
  • Another Acceleron investor, Avoro Capital, which holds about 7% of Acceleron’s stock, said Merck’s deal “drastically undervalues” Acceleron.
  • Related: Activist Investor Thinks Merck Undervalues Acceleron Buy.
  • Hedge fund Darwin Global, which owns 3.8% of Acceleron’s stock, urged shareholders not to tender their shares.
  • Darwin Global Management also said Acceleron execs have settled for a price that was far too low. 
  • By Darwin’s math released Wednesday, the deal undervalues Acceleron by as much as $17 billion, given the blockbuster prospects of both Reblozyl and sotatercept.
  • Another shareholder, Holocene Advisors, said last week that it didn’t plan to tender its shares.
  • Price Action: XLRN shares are up 0.67% at $173.66, BMY shares are down 0.89% at $57.56 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechM&ANewsHealth CareGeneralBloombergBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!